Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with Tax-deficient adult T-cell leukemia-derived cell lines

Cancer Letters

Volumn 257, Issue 2, 2007, Pages 206-215

  Ohsugi, Takeo ^a   Kumasaka, Toshio ^b   Okada, Seiji ^c   Ishida, Takaomi ^d   Yamaguchi, Kazunari ^e   Horie, Ryouichi ^f   Watanabe, Toshiki ^d   Umezawa, Kazuo ^g  

^a Center for Animal Resources and Development   (Japan)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d Graduate School of Frontier Sciences   (Japan)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^f KITASATO UNIVERSITY   (Japan)

^g KEIO UNIVERSITY   (Japan)

Author keywords

ATL; DHMEQ; HTLV I; NF B; NOD SCID 2 microglobulinnull mice

Indexed keywords

BETA 2 MICROGLOBULIN; DEHYDROXYMETHYLEPOXYQUINOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TAX PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL DEATH; CONTROLLED STUDY; DNA BINDING; DRUG EFFICACY; HUMAN T CELL LEUKEMIA VIRUS 1; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; T CELL LEUKEMIA;

ADULT; ANIMALS; APOPTOSIS; BENZAMIDES; BETA 2-MICROGLOBULIN; CELL LINE, TUMOR; CYCLOHEXANONES; GENE PRODUCTS, TAX; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LEUKEMIA, T-CELL; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

HUMAN T-LYMPHOTROPIC VIRUS 1; MUS;

EID: 35148844816     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.07.017     Document Type: Article

References (29)

1. Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D., and Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T cell lymphoma. Proc. Natl. Acad. Sci. USA 77 (1980) 7415-7419
2. Hinuma Y., Nagata K., Hanaoka M., Nakai M., Matsumoto T., Kinoshita K.I., et al. Adult T cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl. Acad. Sci. USA 78 (1981) 6476-6480
3. Watanabe T. HTLV-I-associated diseases. Int. J. Hematol. 66 (1997) 257-278
4. Yamada Y., Tomonaga M., Fukuda H., Hanada S., Utsunomiya A., Tara M., et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br. J. Haematol. 113 (2001) 375-382
5. Yamaoka S., Courtois G., Bessia C., Whiteside S.T., Weil R., Agou F., et al. Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell 93 (1998) 1231-1240
6. Sun S.C., and Yamaoka S. Activation of NF-kB by HTLV-I and implications for cell transformation. Oncogene 24 (2005) 5952-5964
7. Mori N., Fujii M., Ikeda S., Yamada Y., Tomonaga M., Ballard D.W., et al. Constitutive activation of NF-κB in primary adult T cell leukemia cells. Blood 93 (1999) 2360-2368
8. Hironaka N., Mochida K., Mori N., Maeda M., Yamamoto N., and Yamaoka S. Tax-independent constitutive IκB kinase activation in adult T-cell leukemia cells. Neoplasia 6 (2004) 266-278
9. Watanabe M., Ohsugi T., Shoda M., Ishida T., Aizawa S., Maruyama-Nagai M., et al. Dual targeting of transformed and untransformed HTLV-1-infected T-cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T cell leukemia. Blood 106 (2005) 2462-2471
10. Horie R., Watanabe T., and Umezawa K. Blocking NF-κB as a potential strategy to treat adult T-cell leukemia/lymphoma. Drug News Perspect. 19 (2006) 201-209
11. Umezawa K. Inhibition of tumor growth by NF-κB inhibitors. Cancer Sci. 97 (2006) 990-995
12. Matsumoto N., Iinuma H., Sawa T., Takeuchi T., Hirano S., Yoshioka T., et al. Epoxyquinomicins A, B, C and D, new antibiotics from Amycolatopsis. II. Effect on type II collagen-induced arthritis in mice. J. Antibiot. (Tokyo) 50 (1997) 906-911
13. Matsumoto N., Ariga A., To-e S., Nakamura H., Agata N., Hirano S., et al. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett. 10 (2000) 865-869
14. Ariga A., Namekawa J., Matsumoto N., Inoue J., and Umezawa K. Inhibition of tumor necrosis factor-α-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin. J. Biol. Chem. 277 (2002) 24625-24630
15. Kikuchi E., Horiguchi Y., Nakashima J., Kuroda K., Oya M., Ohigashi T., et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res. 63 (2003) 107-110
16. Starenki D.V., Namba H., Saenko V.A., Ohtsuru A., Maeda S., Umezawa K., et al. Induction of thyroid cancer cell apoptosis by a novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin. Clin. Cancer Res. 10 (2004) 6821-6829
17. Matsumoto G., Muta M., Umezawa K., Suzuki T., Misumi K., Tsuruta K., et al. Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-κB inhibitor. Int. J. Oncol. 27 (2005) 1247-1255
18. Watanabe M., Dewan M.Z., Okamura T., Sasaki M., Itoh K., Higashihara M., et al. A Novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int. J. Cancer 114 (2005) 32-38
19. Tatetsu H., Okuno Y., Nakamura M., Matsuno F., Sonoki T., Taniguchi I., et al. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, induces apoptosis in multiple myeloma cells in an IκBα-independent manner. Mol. Cancer Ther. 4 (2005) 1114-1120
20. Matsumoto G., Namekawa J., Muta M., Nakamura T., Bando H., Tohyama K., et al. Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin. Cancer Res. 11 (2005) 1287-1293
21. Ohsugi T., Horie R., Kumasaka T., Ishida A., Ishida T., Yamaguchi K., et al. In vivo antitumor activity of the NF-kB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis 26 (2005) 1382-1388
22. Ohsugi T., Kumasaka T., Ishida A., Ishida T., Horie R., Watanabe T., et al. In vitro and in vivo antitumor activity of the NF-κB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102. Leukemia Res. 30 (2006) 90-97
23. Christianson S.W., Greiner D.L., Hesselton R.A., Leif J.H., Wagar E.J., Schweitzer I.B., et al. Enhanced human CD4+ T cell engraftment in β2-microglobulin-deficient NOD-scid mice. J. Immunol. 158 (1997) 3578-3586
24. Sugamura K., Fujii M., Kannagi M., Sakitani M., Takeuchi M., and Hinuma Y. Cell surface phenotypes and expression of viral antigens of various human cell lines carrying human T-cell leukemia virus. Int. J. Cancer 34 (1984) 221-228
25. Miyoshi I., Kubonishi I., Yoshimoto S., Akagi T., Ohtsuki Y., Shiraishi Y., et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T-cells. Nature 294 (1981) 770-771
26. Ohsugi T., Kumasaka K., and Urano T. Construction of a full-length human T cell leukemia virus type I (HTLV-I) genome from MT-2 cells containing multiple defective proviruses using overlapping polymerase chain reaction. Anal. Biochem. 329 (2004) 281-288
27. Satou Y., Nosaka K., Koya Y., Yasunaga JI., Toyokuni S., and Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 18 (2004) 1357-1363
28. Kinoshita T., Shimoyama M., Tobinai K., Ito M., Ito S., Ikeda S., et al. Detection of mRNA for the tax1/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86 (1989) 5620-5624
29. Furukawa Y., Osame M., Kubota R., Tara M., and Yoshida M. Human T-cell leukemia virus type-1 (HTLV-1) Tax is expressed at the same level in infected cells of HTLV-1-associated myelopathy or tropical spastic paraparesis patients as in asymptomatic carriers but at a lower level in adult T-cell leukemia cells. Blood 85 (1995) 1865-1870